Neurocrine Biosciences Inc. Earnings

Neurocrine Biosciences Inc.’s revenue jumped 11.12% since last year same period to $572.6Mn in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -8.78% fall in its revenue since last 3-months.

Neurocrine Biosciences Inc.’s net profit fell -81.8% since last year same period to $7.9Mn in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -92.34% fall in its net profits since last 3-months.

Neurocrine Biosciences Inc.’s net profit margin fell -83.62% since last year same period to 1.38% in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -91.6% fall in its net profit margins since last 3-months.

Neurocrine Biosciences Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 45.25.

Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.38 - a 41.05% jump from last quarter’s estimates.

Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current year stand at 1.38.

Neurocrine Biosciences Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Neurocrine Biosciences Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.